Frontlight ResearchEarly access
CompletedPhase 1
A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels
Key facts
- Who runs it
- Protalix
- Where
- New Zealand2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 64 people enrolled
- Started
- 23 Mar 2023
- Ended
- 6 Feb 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- PRX-115
- Placebo
- Record updated
- 11 February 2025
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Males or females 18 to 65 years of age, inclusive
- Serum uric acid greater than 6.0 mg/dL (0.35 mmol/L) at the Screening visit
- Body mass index within the range 18.5 to 40 kg/m\^2, inclusive, at the Screening visit
- Women of childbearing potential may be included only if they have a negative beta human chorionic gonadotropin (β-hCG) test result at Screening
- Men and women of childbearing potential and their partners should use double barrier contraception
Who cannot take part
- Had greater than or equal to 1 gout flare in the last year prior to either Screening or Day -1
- History of autoimmune disorders, and/or participant is immunocompromised or treated with immunosuppressive medications
- Concurrent treatment with urate lowering drugs (ULDs)
- Prior exposure to any experimental or marketed uricase (eg, rasburicase [Elitek, Fasturtec], pegloticase [Krystexxa®], pegadricase [SEL-212])
- Has any condition known to have arthritis as a clinical manifestation
- History of significant renal disease, and/or presence of renal stones at either Screening or Day -1
- Has a history of anaphylaxis, severe allergic reactions, or severe atopy
- Has evidence of cardiovascular or cerebrovascular disease
- History of congestive heart failure, New York Heart Association Class III or IV
- Participants with hypertension who are not on stable medication for at least 6 months
- Has uncontrolled type 2 diabetes
- Estimated glomerular filtration rate (eGFR) value less than or equal to 60 mL/min/1.73m\^2
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency or known catalase deficiency
- Has clinical evidence of subcutaneous tophi at either Screening or Day -1
- BP outside the range of 90 to 150 mm Hg for systolic or 50 to 95 mm Hg for diastolic
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a Phase 1, double-blind, placebo-controlled, single ascending dose study in participants with elevated uric acid levels. This study will be conducted in approximately 64 adult male and female participants in the dose escalation phase.
The 2 groups in the trial
- PRX-115Treatment being tested
Participants will receive a single dose of PRX-115 by IV infusion
- PlaceboPlacebo, for comparison
Participants will receive a single dose of placebo by IV infusion
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels.
- Record updated
- 11 February 2025